Literature DB >> 1185222

Progressive familial myoclonus epilepsy.

H Rustam, T Hamdi, S Witri.   

Abstract

Seven cases of progressive familial myoclonus epilepsy occurring in three families are presented. The patients were in different stages of the illness. The EEG was abnormal in all. It is suggested that these cases belong clinically to the Lafora bodies group. Nystagmus and optic atrophy, seen in one patient, have not been described previously. Myoclonic jerks did not respond to treatment with diazepam and ethosuximide.

Entities:  

Mesh:

Year:  1975        PMID: 1185222      PMCID: PMC492112          DOI: 10.1136/jnnp.38.9.845

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  LAFORA'S DISEASE. DISTINCT CLINICO-PATHOLOGIC FORM OF UNVERRICHT'S SYNDROME.

Authors:  G A SCHWARZ; M YANOFF
Journal:  Arch Neurol       Date:  1965-02

2.  Progressive familial myoclonic epilepsy in three families: its clinical features and pathological basis.

Authors:  D G HARRIMAN; J H MILLAR; A C STEVENSON
Journal:  Brain       Date:  1955-09       Impact factor: 13.501

3.  Myoclonus epilepsy as a symptom of diffuse neuronal disease.

Authors:  C W WATSON; D DENNY-BROWN
Journal:  AMA Arch Neurol Psychiatry       Date:  1953-08

4.  Progressive myoclonic epilepsy with Lafora's bodies. A clinico-pathological study.

Authors:  E S Lope; S Ramón; S R Junquera; A B Berenguel
Journal:  Acta Neurol Scand       Date:  1974       Impact factor: 3.209

5.  Progressive myoclonus epilepsy without Lafora bodies.

Authors:  W B Matthews; D A Howell; D L Stevens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-04       Impact factor: 10.154

6.  Progressive myoclonus epilepsy with Lafora inclusion bodies. I. Clinical, genetic, histopathologic, and biochemical aspects.

Authors:  R Janeway; J R Ravens; L A Pearce; D L Odor; K Suzuki
Journal:  Arch Neurol       Date:  1967-06
  6 in total
  1 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.